» Articles » PMID: 39201315

Alterations in Tumor Aggression Following Androgen Receptor Signaling Restoration in Canine Prostate Cancer Cell Lines

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Aug 29
PMID 39201315
Authors
Affiliations
Soon will be listed here.
Abstract

In prostate cancer (PCa), androgens upregulate tumorigenesis, whereas in benign tissue, the revival of androgen receptor (AR) signaling suppresses aggressive behaviors, suggesting therapeutic potential. Dogs, natural PCa models, often lack AR in PCa. We restored AR in dog PCa to investigate resultant characteristics. Three AR-null canine PCa lines (1508, Leo, 1258) were transfected with canine wild-type AR and treated with dihydrotestosterone (DHT). In 1508, AR restoration decreased clonogenicity ( = 0.03), viability ( = 0.004), migration ( = 0.03), invasion ( = 0.01), and increased expression of the tumor suppressor , an AR transcriptional target ( = 0.001). In Leo, AR decreased clonogenicity ( = 0.04) and the expression of another AR transcriptional target ( < 0.001) and increased the expression of ( = 0.01). In 1258, AR increased migration ( = 0.006) and invasion ( = 0.03). Epithelial-mesenchymal transition (EMT) marker (, , ) expression increased with AR restoration in Leo and 1258 but not 1508; siRNA vimentin knockdown abrogated AR-induced 1258 migration only. Overall, 1508 showed AR-mediated tumor suppression; AR affected proliferation in Leo but not migration or invasion; and EMT and AR regulated migration and invasion in 1258 but not proliferation. This study highlights the heterogeneous nature of PCa in dogs and cell line-specific effects of AR abrogation on aggressive behaviors.

References
1.
Jagannathan V, Hitte C, Kidd J, Masterson P, Murphy T, Emery S . Dog10K_Boxer_Tasha_1.0: A Long-Read Assembly of the Dog Reference Genome. Genes (Basel). 2021; 12(6). PMC: 8228171. DOI: 10.3390/genes12060847. View

2.
Packeiser E, Taher L, Kong W, Ernst M, Beck J, Hewicker-Trautwein M . RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures. Cancer Cell Int. 2022; 22(1):54. PMC: 8812184. DOI: 10.1186/s12935-021-02422-9. View

3.
Sena L, Kumar R, Sanin D, Thompson E, Rosen D, Dalrymple S . Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC. J Clin Invest. 2022; 132(23). PMC: 9711876. DOI: 10.1172/JCI162396. View

4.
Sammarco A, Gomiero C, Beffagna G, Cavicchioli L, Ferro S, Michieletto S . Epithelial-to-Mesenchymal Transition and Phenotypic Marker Evaluation in Human, Canine, and Feline Mammary Gland Tumors. Animals (Basel). 2023; 13(5). PMC: 10000046. DOI: 10.3390/ani13050878. View

5.
Franken N, Rodermond H, Stap J, Haveman J, van Bree C . Clonogenic assay of cells in vitro. Nat Protoc. 2007; 1(5):2315-9. DOI: 10.1038/nprot.2006.339. View